Education
About Us
Working with TipRanks
Follow Us
Oncolytics Biotech (ONCY)
NASDAQ:ONCY
ONCY Analyst Ratings
Strong Buy
4 Buy
1 Hold
0 Sell
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months
ONCY Stock 12 Month Forecast
Average Price Target
$4.39
▲(330.39% Upside)
| Highest Price Target$7.00 | Average Price Target$4.39 | Lowest Price Target$2.55 |
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.
Detailed List of Analyst Forecasts
Detailed List of Analyst Forecasts
Lake Street
$7
Buy
586.27%
Upside
Initiated
08/13/25
H.C. Wainwright
$5
Buy
390.20%
Upside
Reiterated
08/12/25
Oncolytics Biotech's Transformative Year: Advancements in mPDAC Treatment with PelareorepWe assess Oncolytics Biotech using a discounted cash flow (DCF)-based valuation methodology. We assign probabilities of success for pelareorep of 45% in HR+/HER2- mBC 3L+ and 25% in pancreatic cancer. We include a revenue build tied to the clinical development of pelareorep through its anticipated potential launch in 2027E, leading to a moderate present value. We model annual gross equity raises of $100M-$200M from 2025E-2027E, which could dilute existing shareholders. We employ a 12% discount rate and a terminal multiple of 6.0x. We include a Canadian dollar to U.S.
Maxim Group
$3
Buy
194.12%
Upside
Reiterated
08/12/25
RBC Capital
$3.62→$2.53
Buy
148.48%
Upside
Reiterated
08/08/25
JonesTrading
―
Hold
―
Reiterated
08/08/25
TR | OpenAI - 4o
―
Hold
―
Reiterated
05/02/25
Canaccord Genuity
$5
Buy
390.20%
Upside
Reiterated
11/12/24
Raymond James
$2.17→$2.53
Buy
148.48%
Upside
Reiterated
09/20/24
Ranks
Any
Analyst Rating
Any
Upside/ Downside
Any
Action
Any
Lake Street
$7
Buy
586.27%
Upside
Initiated
08/13/25
H.C. Wainwright
$5
Buy
390.20%
Upside
Reiterated
08/12/25
Oncolytics Biotech's Transformative Year: Advancements in mPDAC Treatment with PelareorepWe assess Oncolytics Biotech using a discounted cash flow (DCF)-based valuation methodology. We assign probabilities of success for pelareorep of 45% in HR+/HER2- mBC 3L+ and 25% in pancreatic cancer. We include a revenue build tied to the clinical development of pelareorep through its anticipated potential launch in 2027E, leading to a moderate present value. We model annual gross equity raises of $100M-$200M from 2025E-2027E, which could dilute existing shareholders. We employ a 12% discount rate and a terminal multiple of 6.0x. We include a Canadian dollar to U.S.
Maxim Group
$3
Buy
194.12%
Upside
Reiterated
08/12/25
RBC Capital
$3.62→$2.53
Buy
148.48%
Upside
Reiterated
08/08/25
JonesTrading
―
Hold
―
Reiterated
08/08/25
TR | OpenAI - 4o
―
Hold
―
Reiterated
05/02/25
Canaccord Genuity
$5
Buy
390.20%
Upside
Reiterated
11/12/24
Raymond James
$2.17→$2.53
Buy
148.48%
Upside
Reiterated
09/20/24
Best Analysts Covering Oncolytics Biotech
1 Month
xxx
Success Rate
9/21 ratings generated profit
Average Return
+5.85%
reiterated a xxx
rating 4 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 42.86% of your transactions generating a profit, with an average return of +5.85% per trade.
3 Months
xxx
Success Rate
12/27 ratings generated profit
Average Return
-5.80%
reiterated a xxx
rating 8 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 44.44% of your transactions generating a profit, with an average return of -5.80% per trade.
1 Year
Success Rate
10/27 ratings generated profit
Average Return
-8.08%
reiterated a buy rating 8 days ago
Copying Douglas Miehm's trades and holding each position for 1 Year would result in 37.04% of your transactions generating a profit, with an average return of -8.08% per trade.
2 Years
xxx
Success Rate
8/27 ratings generated profit
Average Return
-15.96%
reiterated a xxx
rating 8 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 29.63% of your transactions generating a profit, with an average return of -15.96% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.
ONCY Analyst Recommendation Trends
Rating
Apr 25
May 25
Jun 25
Jul 25
Aug 25
Strong Buy
5
7
4
7
8
Buy
0
0
0
0
0
Hold
4
6
5
2
1
Sell
1
1
1
0
0
Strong Sell
0
0
0
0
0
total
10
14
10
9
9
Each month's total comprises the sum of three months' worth of ratings.
ONCY Financial Forecast
ONCY Stock Forecast FAQ
What is ONCY’s average 12-month price target, according to analysts?
Based on analyst ratings, Oncolytics Biotech’s 12-month average price target is 4.39.
What is ONCY’s upside potential, based on the analysts’ average price target?
Oncolytics Biotech has 330.39% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is ONCY a Buy, Sell or Hold?
Oncolytics Biotech has a consensus rating of Strong Buy which is based on 4 buy ratings, 1 hold ratings and 0 sell ratings.
What is Oncolytics Biotech’s price target?
The average price target for Oncolytics Biotech is 4.39. This is based on 5 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $7.00 ,the lowest forecast is $2.55. The average price target represents 330.39% Increase from the current price of $1.02.
The highest analyst price target is $7.00 ,the lowest forecast is $2.55. The average price target represents 330.39% Increase from the current price of $1.02.
What do analysts say about Oncolytics Biotech?
Oncolytics Biotech’s analyst rating consensus is a Strong Buy. This is based on the ratings of 5 Wall Streets Analysts.
How can I buy shares of ONCY?
Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.